Evidence map›Paper›PMID 42186257›Full record

ReviewPhytotherapy research : PTR2026

Natural Plant Bioactives as Regulators of Histone Modifications: Bridging Epigenetics and Anticancer Therapy.

Mengxiao Wang, Junyi Liang, Xinping Zhu, Yushuang Xing, Shijun Chang, Di Jia, Weiming Zhao

Abstract readReview
In one paragraph

Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengxiao WangHeilongjiang University of Chinese Medicine, Harbin, China.ORCID https://orcid.org/0009-0009-2313-0303
Junyi LiangHeilongjiang University of Chinese Medicine, Harbin, China.ORCID https://orcid.org/0009-0000-3011-5819
Xinping ZhuHeilongjiang University of Chinese Medicine, Harbin, China.
Yushuang XingGraduate Department, Qiqihar Medical University, Qiqihar, Heilongjiang, China.
Shijun ChangHeilongjiang University of Chinese Medicine, Harbin, China.
Di JiaDepartment of Medical Technology, Qiqihar Medical College, Qiqihar, China.
Weiming ZhaoHeilongjiang University of Chinese Medicine, Harbin, China.

Funding

Heilongjiang University of Chinese Medicine funded projects 15041240014National Natural Science Foundation of China 82404700Research Projects of the Heilongjiang Provincial Administration of Traditional Chinese Medicine ZHY2025-210
6 · The paper itself

Abstract

Cancer remains a leading cause of global mortality, with tumor heterogeneity, recurrence, metastasis, and drug resistance posing significant challenges to conventional therapies, which are often limited by toxicity and efficacy. Epigenetic regulation, particularly histone modifications such as methylation, acetylation, phosphorylation, and lactylation, plays a pivotal role in orchestrating gene expression and tumor progression, representing promising yet complex therapeutic targets. Bioactive compounds derived from natural plants, characterized by multi-target activity and low toxicity, have emerged as potent modulators of histone modifications, capable of influencing tumor growth, metastasis, and the tumor microenvironment. Here, we provide a comprehensive review of recent advances elucidating how natural products influence cancer progression and reshape the tumor immune microenvironment by regulating histone modifications. We integrate current knowledge of key histone marks, modifying enzymes, and signaling pathways, proposing a unified framework linking natural compounds, epigenetic regulation, and tumorigenesis. By uncovering these molecular mechanisms, we highlight that plant bioactive compounds can reshape the tumor immune microenvironment through histone modifications to inspire the development of novel, safer, and more effective anticancer agents.

Indexed as

Antineoplastic Agents, PhytogenicBiological ProductsEpigenesis, GeneticHistonesNeoplasmsHumansSignal TransductionTumor MicroenvironmentAntineoplastic Agents, PhytogenicBiological ProductsHistones

Identifiers

PMID42186257
PMCPMC13436294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.